Comprehensive Transthyretin Amyloidosis Treatment Market Forecast 2025-2034: Growth Trends and Strategic Shifts

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Transthyretin Amyloidosis Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
A robust expansion has been observed in the transthyretin amyloidosis treatment market in preceding years. The market value will increase from $5.52 billion in 2024 to $5.95 billion in 2025, advancing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to the growth during the historic period include enhanced disease awareness, advancements made in diagnostic instruments, development and sanctioning of drugs, patient advocacy, and support, collaboration in research.

Transthyretin Amyloidosis Treatment Market Size Forecast: What's the Projected Valuation by 2029?
It is anticipated that the market for transthyretin amyloidosis treatment will experience robust expansion in the forthcoming years, increasing to a valuation of $8.04 billion by 2029, with a compound annual growth rate (CAGR) of 7.8%. The projected growth in this period can be linked back to several contributing factors, including the development of an extensive therapeutic pipeline, an uptick in genetic screenings, worldwide initiatives for raising awareness about rare diseases, personalized treatment plans, and enhanced accessibility to treatment options. The evolution of the market in this period will be marked by emerging trends such as the development of combination therapies, strategic alliances for drug creation, focus on addressing peripheral and heart-related symptoms, rollout of patient information programs, and the inclusion of real-world evidence in treatment protocols.

View the full report here:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

What Are the Drivers Transforming the Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatment market's growth is anticipated to accelerate due to increasing investments in research and development. These investments aimed at advancing scientific discoveries, developing innovative technologies, and improving established processes, are pivotal for creating advanced treatment methodologies for transthyretin amyloidosis, including new drugs, gene therapies, and precision medicine techniques. This largely enhances the efficacy and specificity of patient treatment options. For example, in 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company involved in the development of Vutrisiran, a treatment for ATTR amyloidosis, elevated its R&D investment from $792,156 in 2021 to $883,015, marking an 11.49% increase. Therefore, increased R&D expenses contribute significantly to the growth of the transthyretin amyloidosis treatment market. Elderly population demographics are also predicted to contribute significantly to the expansion of the transthyretin amyloidosis treatment market. The term 'aging population' characterizes a demographic trend where the median age of a population rises due to falling birth rates and increased life expectancy. Being a major risk factor for transthyretin amyloidosis (ATTR), an aging population leads to an increased prevalence of the disease, thereby growing the patient population seeking treatment. For instance, the World Health Organization, a Switzerland-based international public health agency of the UN, reported in October 2022 that every country is witnessing a population growth in the older demographic. Furthermore, by 2030, one in six individuals globally will be over the age of 60. Hence, the expanding demographics of the elderly population are a key driver for the expansion of the transthyretin amyloidosis treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

What Long-Term Trends Will Define the Future of the Transthyretin Amyloidosis Treatment Market?
Leading companies in the transthyretin amyloidosis treatment market are concentrating their efforts on the creation of innovative and targeted therapies, such as orphan drugs, to improve patient results and broaden the scope of treatment alternatives. The orphan drug, Eplontersen, has been specifically developed to address transthyretin amyloidosis, often gaining regulatory perks to assist its progression. For example, in March 2023, the Canadian biotech research firm, Ionis Pharmaceuticals, Inc., obtained The Food and Drug Administration (FDA) endorsement of a new drug application for Eplontersen, a trial orphan drug devised for the therapy of familial transthyretin-mediated amyloid leading to progressively worsening polyneuropathy. Eplontersen is a medicinal product created to reduce the production of transthyretin (TTR) protein, tackling both hereditary and non-hereditary forms of ATTR amyloidosis (amyloid transthyretin amyloidosis). In 2022, the FDA awarded Eplontersen the status of an orphan drug.

Which Segments in the Transthyretin Amyloidosis Treatment Market Offer the Most Profit Potential?
The transthyretin amyloidosis treatment market covered in this report is segmented -

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp

Which Firms Dominate the Transthyretin Amyloidosis Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

Which Regions Offer the Highest Growth Potential in the Transthyretin Amyloidosis Treatment Market?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.